Sultamicillin: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use

Drugs

Volumn 37, Issue 4, 1989, Pages 491-522

  Friedel, Heather A ^a   Campoli Richards, Deborah M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; SULBACTAM; SULTAMICILLIN;

ANIMAL; BACTERIAL INFECTION; BACTERIUM; DRUG EFFECT; HUMAN; MICROBIOLOGY; REVIEW;

AMPICILLIN; ANIMAL; ANTIBIOTICS, COMBINED; BACTERIA; BACTERIAL INFECTIONS; HUMAN; SULBACTAM;

EID: 0024652292     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198937040-00005     Document Type: Article

References (137)

1. Antimicrobial combinations in the therapy of infections due to Gram-negative bacilli
2. Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations
3. Clinical study of sultamicillin
4. Sultamicillin: antimicrobial activity and clinical investigation of respiratory tract infections
5. Comparative activity of β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with β-lactams against β-lactamase-producing anaerobes
6. A double-blind comparative study of sultamicillin and potassium penicillin V in the treatment of childhood streptococcal pharyngitis
7. Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children
8. Sultamicillin in the treatment of gonorrhoea caused by penicillin sensitive and penicillinase producing strains of Neisseria gonorrhoeae
9. Effect of sulbactam-ampicillin on ampicillin-resistant bacteria in two Swiss hospitals
10. Evaluation of sultamicillin in acute lacunar tonsillitis: a comparative double blind study with cefaclor
11. Sultamicillin (CP-49,952): evaluation of two dosage schedules in urinary infection
12. Mutual pro-drugs of β-lactam antibiotics and β-lactamase inhibitors
13. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests
14. Excess of ampicillin rashes associated with allopurinol or hyperuricemia
15. Sulbactam/ampicillin: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use
16. Sulbactam/ampicillin: effects on glucose metabolism in diabetics with soft tissue infection
17. Fundamental and clinical evaluations of sultamicillin in obstetrical and gynecological field
18. Aminopenicillins and superinfection by Gram-negative rods
19. Clinical, bacteriological and pharmacokinetic results from an open trial of sultamicillin in patients with acute exacerbations of chronic bronchitis
20. Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid
21. Pharmacokinetics of sultamicillin in mice, rats, and dogs
22. Valutazione clinica della sultamicillina in confronto alia amoxicillina nel trattamento delle infezioni urinarie, respiratorie ed ORL
23. Two regimens of sultamicillin in treating uncomplicated gonorrhoea
24. Pharmacokinetics of sulbactam/ampicillin in humans: a review
25. Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes
26. Effect of sultamicillin in otorhinolaryngological infections
27. Clinical studies of sultamicillin in urinary tract infection
28. Pharmacokinetics and bactericidal activity of sultamicillin in infants and children
29. Sultamicillin in the treatment of superficial skin and soft tissue infections in children
30. Bacteriological studies on sultamicillin
31. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/ amoxycillin in human volunteers
32. A three-way crossover study to compare the pharmacokinetics and acceptability of sultamicillin at two dose levels with that of ampicillin
33. Studies on sultamicillin in the field of ophthalmology
34. Clinical study on sultamicillin in the treatment of respiratory tract infection
35. Clinical studies on sultamicillin in the treatment of respiratory tract infections
36. Microbiological and clinical studies on sultamicillin
37. Fundamental and clinical studies on sultamicillin in the field of dermatology
38. Clinical evaluations of sultamicillin in respiratory tract infection
39. Susceptibility of Haemophilus decreyi to ampicillin and sulbactam in vitro
40. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination
41. In-vitro activity of ampicillin/sulbactam against cefoxitin-resistant anaerobic bacteria
42. Pharmacokinetic and therapeutic trial of sultamicillin in acute sinusitis
43. Sultamicillin (ampicillin-sulbactam) in the treatment of acute otitis media in children
44. Fundamental and clinical studies on sultamicillin in the urological field
45. The absorption, distribution and excretion of sultamicillin tosilate in experimental animals
46. Clinical evaluation of sultamicillin in the field of respiratory tract infections
47. Comparative studies of sultamicillin and cefadroxil in complicated urinary tract infections
48. Clinical studies of sultamicillin in the otorhinolaryngeal field
49. Evaluation of sultamicillin in acute suppurative otitis media and acute exacerbation of chronic otitis media: a comparative double blind study with cefaclor
50. Clinical study of sultamicillin in the treatment of urinary tract infections
51. Antibacterial activity of sultamicillin
52. Comparative study on sultamicillin and bacampicillin in the treatment of respiratory tract infections
53. Epidemiological and therapeutic studies of gonorrheal infection: clinical efficacy of sultamicillin
54. Clinical application of sultamicillin in the field of ob-gyn
55. Laboratory and clinical studies on sultamicillin with special reference to the treatment of respiratory tract infections
56. Fundamental and clinical studies on sultamicillin (SBTPC) in urological fields
57. Laboratory and clinical studies on sultamicillin in otorhinolaryngological field
58. Clinical studies on sultamicillin in chronic complicated urinary tract infections
59. Clinical significance of respiratory infection caused by Branhamella catarrhalis with special reference to β-lactamase producing strains
60. Clinical studies on sultamicillin in the treatment of respiratory infections
61. Clinical study on sultamicillin in the respiratory tract infections
62. Clinical evaluation for sultamicillin on the complicated urinary tract infections and the infections of male genital organs in the aged
63. Bacteriological and pharmacokinetic studies and clinical experiences with sultamicillin, a new antibiotic and mutual prodrug in the field of surgery
64. A laboratory study on a newly developed penicillin derivative, sultamicillin, and a clinical evaluation in respiratory infections
65. Clinical study of sultamicillin on respiratory tract infection
66. A comparative double-blind study of sultamicillin and bacampicillin
67. Clinical trial of sultamicillin in urinary tract infections
68. Clinical studies of sultamicillin in urological field
69. Examination of pharmacokinetics and intestinal flora following 15 days of sultamicillin, ampicillin administration
70. Basic and clinical studies on sultamicillin
71. Clinical evaluation of sultamicillin in patients with complicated urinary tract infections
72. Fundamental and clinical studies on sultamicillin in urinary tract and gonorrheal infections
73. Clinical investigation of sultamicillin in otorhinolaryngological field
74. Microbiological, pharmacokinetic and clinical studies of sultamicillin in ophthalmology
75. In vitro antibacterial activity of sultamicillin
76. Amoxicillin and ampicillin: rashes equally likely
77. Sultamicillin: a new antibiotic in the treatment of persistent lower respiratory tract infections caused by Haemophilus influenzae
78. Concentrations of sultamicillin in serum and middle ear fluid of children with chronic otitis media with effusion
79. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides
80. Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography
81. Sultamicillin (ampicillin-sulbactam) in two oral dosage regimens vs amoxicillin in the treatment of acute otitis media
82. Sultamicillin: pharmacokinetics and clinical effects
83. Clinical studies on sultamicillin
84. Clinical trials of sultamicillin (ester of sulbactam-ampicillin) on the skin and soft tissue infections in the field of surgery
85. Fundamental and clinical studies on sultamicillin
86. Clinical investigation of sultamicillin in the infections of the otorhinolaryngological field
87. Potential for bleeding with the new beta-lactam antibiotics
88. Studies on sultamicillin tissue concentration and clinical efficacy on infectious diseases
89. Laboratory and clinical studies on sultamicillin
90. Whole animal models in safety evaluation
91. Fundamental and clinical studies of sultamicillin in urinary tract infections
92. Sulbactam-induced diarrhea. Abstract no. 49
93. Studies on sultamicillin in urinary tract infections
94. Clinical evaluation of sultamicillin in surgical infection with special reference to the treatment of skin and soft tissue infections
95. Clinical studies on sultamicillin, a new oral antibiotic, in the urinary tract infection and gonorrheal infection
96. Clinical evaluation of sultamicillin on the lower respiratory tract infection
97. Clinical studies on sultamicillin in the treatment of respiratory tract infections
98. Clinical and laboratory studies on SBTPC (sultamicillin) in the field of obstetrics and gynecology
99. Clinical investigation on sultamicillin in urinary tract infection
100. Laboratory and clinical studies on sultamicillin
101. The effect of sultamicillin on human fecal flora and characters of feces
102. Clinical studies on sultamicillin in the treatment of respiratory tract infections
103. Fundamental and clinical studies of sultamicillin in dermatological field
104. Serum bactericidal activity of ampicillin and mezlocillin with and without sulbactam
105. Sultamicillin use in otitis media: penetration of sulbactam, a beta-lactamase inhibitor, and ampicillin into middle-ear fluid
106. Clinical studies of SBTPC (sultamicillin) in the field of dermatology
107. Efficacy of ampicillin plus a β-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus
108. Clinical study on sultamicillin
109. Antibacterial activity of sultamicillin against anaerobes
110. Antimicrobial and clinical studies on sultamicillin
111. Laboratory and clinical studies of sultamicillin in dermatological fields
112. β-Lactamase inhibitors
113. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins
114. A study on antimicrobial activity and clinical usefulness of sultamicillin for urinary tract infection and gonococcal urethritis
115. Fundamental and clinical studies on sultamicillin in the surgical field
116. Clinical studies on sultamicillin in the field of obstetrics and gynecology
117. Clinical study of sultamicillin on chronic complicated urinary tract infections
118. Clinical experience with sultamicillin in the field of dermatology
119. Antibacterial activity of sultamicillin and its affinity to penicillin-binding proteins of various bacteria
120. Clinical experience with sultamicillin in infections of oral region
121. Fundamental and clinical studies of sultamicillin in the surgical field